Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This is the first human study of an experimental cancer drug called TQB6411. Researchers are testing its safety, how it moves through the body, and looking for early signs that it might help control advanced cancers. The study will enroll 216 adults whose cancers have progressed …

This study is testing an investigational drug called TQB2102 for people with advanced non-small cell lung cancer that has a specific genetic change (HER2 abnormality) and has stopped responding to standard treatments. The drug is designed to deliver a powerful cancer-killing agen…

This study is testing a new combination of three treatments—an experimental immunotherapy (TQB2868), a targeted drug (anlotinib), and standard chemotherapy—for people newly diagnosed with advanced pancreatic cancer. The goal is to see if this combination can better control the ca…

This study is testing whether a new drug called TQB2930, when given with chemotherapy, works better than the current standard treatment for people with advanced HER2-positive breast cancer that has worsened after at least two prior anti-HER2 treatments. It will involve 416 adults…

This study is testing a new drug called LM-108, given alongside an immunotherapy drug (penpulimab) and standard chemotherapy, for people with advanced solid tumors that cannot be removed by surgery. The main goals are to find a safe dose and see if this combination can help contr…

This study is testing an experimental drug called TQB2102 for people with advanced bile duct cancer that has a specific marker called HER2. The main goals are to find the safest and most effective dose and to see if the drug helps shrink tumors. The trial is for adults whose canc…

This is a first-in-human study to test the safety and how the body processes a new drug called TQB2934 for multiple myeloma, a type of blood cancer. The drug is given as a shot under the skin and works by guiding the body's own immune T-cells to find and kill the cancer cells. Th…

This study is testing whether a new drug called TQB2102 works better than the current standard treatment for shrinking HER2-positive breast cancer tumors before surgery. It will involve 544 patients with early-stage breast cancer who haven't had prior cancer treatment. The main g…